Advertisement

Advertisement

BNTC Stock Latest News

Guggenheim downgrades Benitec to Neutral, terminates coverage

The FlyGuggenheim downgrades Benitec to Neutral, terminates coverage

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

PremiumThe Fly

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

6d ago

Benitec Biopharma Announces Board Changes and New Director

PremiumCompany Announcements

Benitec Biopharma Announces Board Changes and New Director

18d ago

Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained

PremiumRatings

Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained

21d ago

Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia

PremiumRatings

Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia

1M ago

Benitec Biopharma initiated with an Outperform at Evercore ISI

PremiumThe FlyBenitec Biopharma initiated with an Outperform at Evercore ISI

1M ago

Reiterating Buy on Benitec: Promising Early BB-301 Data in OPMD Underpin $32 12‑Month Target

Ratings

Reiterating Buy on Benitec: Promising Early BB-301 Data in OPMD Underpin $32 12‑Month Target

3M ago

Benitec Biopharma announces interim Phase 1b/2a study of BB-301

The Fly

Benitec Biopharma announces interim Phase 1b/2a study of BB-301

3M ago

PremiumRatings

Benitec Biopharma: Emerging BB-301 Clinical Profile and Upcoming Data Catalyst Support Buy Rating and $32 Target

4M ago

Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year

PremiumThe Fly

Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year

4M ago

Benitec Biopharma files to sell 1.48M shares of common stock for holders

PremiumThe Fly

Benitec Biopharma files to sell 1.48M shares of common stock for holders

5M ago

Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study

PremiumThe Fly

Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study

5M ago

Benitec Biopharma Concludes 2025 Annual Stockholders Meeting

PremiumCompany AnnouncementsBenitec Biopharma Concludes 2025 Annual Stockholders Meeting

7M ago

Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright

The Fly

Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright

7M ago

Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating

Ratings

Benitec Biopharma: Strong Financial Position and Promising Clinical Developments Justify Buy Rating

7M ago

Citizens JMP healthcare analysts hold an analyst/industry conference

PremiumThe Fly

Citizens JMP healthcare analysts hold an analyst/industry conference

7M ago

Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses

PremiumCompany Announcements

Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses

7M ago

Benitec Biopharma reports Q1 EPS (22c), consensus (33c)

PremiumThe Fly

Benitec Biopharma reports Q1 EPS (22c), consensus (33c)

7M ago

Benitec Biopharma Announces $100 Million Public Offering

PremiumCompany Announcements

Benitec Biopharma Announces $100 Million Public Offering

7M ago

Benitec Biopharma $100M share Spot Secondary priced at $13.50

PremiumThe FlyBenitec Biopharma $100M share Spot Secondary priced at $13.50

7M ago

Benitec Biopharma announces common stock offering, no amount given

The Fly

Benitec Biopharma announces common stock offering, no amount given

7M ago

Positive Buy Rating for BB-301 Driven by Promising Trial Results and Potential Market Acceleration

Ratings

Positive Buy Rating for BB-301 Driven by Promising Trial Results and Potential Market Acceleration

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >